Beigene Ltd
SSE:688235

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
SSE:688235
Watchlist
Price: 276.8 CNY -0.27%
Market Cap: 247B CNY

Beigene Ltd
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Beigene Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Beigene Ltd
SSE:688235
Gross Profit
ÂĄ23B
CAGR 3-Years
52%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Tanvex BioPharma Inc
TWSE:6541
Gross Profit
-NT$195.9m
CAGR 3-Years
-146%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Polaris Group
TWSE:6550
Gross Profit
-NT$76.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Beigene Ltd
Glance View

Market Cap
247B CNY
Industry
Biotechnology

BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.

Intrinsic Value
194.42 CNY
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Beigene Ltd's Gross Profit?
Gross Profit
23B CNY

Based on the financial report for Dec 31, 2024, Beigene Ltd's Gross Profit amounts to 23B CNY.

What is Beigene Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
56%

Over the last year, the Gross Profit growth was 56%. The average annual Gross Profit growth rates for Beigene Ltd have been 52% over the past three years , 56% over the past five years .

Back to Top